Results 211 to 220 of about 11,731,529 (403)
Fallacy of the log-normal approximation to optimal portfolio decision-making over many periods [PDF]
Robert C. Merton, Paul A. Samuelson
openalex +1 more source
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy+12 more
wiley +1 more source
Families' Experiences of Surrogate Decision-Making and Challenges of Shared Decision-Making: A Cross-Sectional Study. [PDF]
Yamamoto K.
europepmc +1 more source
Psychological Study of Human Judgment: Implications for Investment Decision Making [PDF]
Paul Slovic
openalex +1 more source
Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen+6 more
wiley +1 more source
The Role of Personality Traits and Decision-Making Styles in Career Decision-Making Difficulties. [PDF]
Aydemir Dev M, Bayram Arlı N.
europepmc +1 more source
Decision-making problems of the council of agriculture ministers [PDF]
Ulrich Koester
openalex +1 more source
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti+8 more
wiley +1 more source
Decoding uncertainty for clinical decision-making. [PDF]
Tsaneva-Atanasova K+2 more
europepmc +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia+17 more
wiley +1 more source